Alembic Pharmaceuticals Ltd Analyst Rating
based on 12 analysts
38.46%
Buy
38.46%
Hold
23.08%
Sell
Based on 12 analysts offering long term price targets for Alembic Pharmaceuticals Ltd. An average target of ₹1161.92
Source: S&P Global Market Intelligence
Alembic Pharmaceuticals Ltd Share analysis
Alembic Pharmaceuticals Ltd price forecast by 12 analysts
Upside of11.69%
High
₹1412
Target
₹1161.92
Low
₹895
Alembic Pharmaceuticals Ltd target price ₹1161.92, a slight upside of 11.69% compared to current price of ₹1037.85. According to 12 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Alembic Pharmaceuticals Ltd revenue growth forecast
Expected growth rate Q1, FY2026:20.27%
Forecast
Actual
Including amortisation and stock based compensations
Alembic Pharmaceuticals Ltd EPS growth forecast
EPS estimate Q1, FY2026:36.16%
Forecast
Actual
Source: S&P Global Market Intelligence
Alembic Pharmaceuticals Ltd Performance
Day's Low
Day's High
₹1,020.65₹1,043.452 Week's Low
52 Week's High
₹710.25₹1,303.9
| Returns % | |
| 1 Month Return | -8.8 % |
| 3 Month Return | -6.04 % |
| 1 Year Return | + 39.97 % |
| Market Stats | |
| Previous Close | ₹1,040.35 |
| Open | ₹1,041.30 |
| Volume | 54.80K |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹20,449.44Cr |
Alembic Pharmaceuticals Ltd Key Statistics
| P/E Ratio | 32.17 |
| PEG Ratio | 6.08 |
| Market Cap | ₹20,449.44 Cr |
| P/B Ratio | 3.93 |
| EPS | 31.33 |
| Dividend Yield | 1.12 |
| Sector | Pharmaceuticals |
| ROE | 14.3 |
Alembic Pharmaceuticals Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| HOLD | ₹20,449.44 Cr | 17.98% | 0.55 | ₹615 Cr | ₹6,228 Cr | |
| BUY | ₹14,159.53 Cr | -2.2% | 0.52 | ₹602 Cr | ₹2,851 Cr | |
| BUY | ₹73,248.19 Cr | 38.18% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| HOLD | ₹95,350.73 Cr | 54.5% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹57,851.74 Cr | 23.94% | 0.53 | NA | NA |
About Alembic Pharmaceuticals Ltd
Share Price: ₹1037.85 per share as on 21 Nov, 2024 04:01 PM
Market Capitalisation: ₹20,449.44Cr as of today
Revenue: ₹1,647.98Cr as on September 2024 (Q3 24)
Net Profit: ₹153.14Cr as on September 2024 (Q3 24)
Listing date: 20 Sep, 2011
Chairperson Name: Chirayu R Amin
| Organisation | Alembic Pharmaceuticals Ltd |
| Headquarters | Vadodara |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Secures USFDA Approval for Ivabradine - 12 Nov, 2024
Alembic Pharmaceuticals has received final USFDA approval for Ivabradine Tablets, which target a market size of $145.3 million. This adds to their total of 218 ANDA approvals.
Alembic Pharma Secures USFDA Approval for Hypertension Drug - 11 Nov, 2024
Alembic Pharmaceuticals has received final USFDA approval for Diltiazem Hydrochloride Extended-Release Capsules, enhancing its generics portfolio. The market size for this drug is estimated at $105.3 million.
Alembic Pharma Reports Growth in Sales and Profit - 08 Nov, 2024
Alembic Pharma's September 2024 consolidated net sales increased by 3.33% YoY to Rs 1,647.98 crore, with net profit up 12.33%. However, Motilal Oswal cut earnings estimates due to operational challenges.
Alembic Pharma Reports Strong Q2FY25 Financials - 07 Nov, 2024
Alembic Pharmaceuticals announced a 12% YoY increase in net profit to Rs 153 crore for Q2FY25, with revenues up 3% to Rs 1,648 crore. The growth was attributed to strong performance in domestic formulations and the US market, despite challenges in the API segment. The company also received positive FDA inspection results for its Oncology facility.
Alembic Pharma Receives USFDA Approval for Generic Drug - 22 Oct, 2024
Alembic Pharmaceuticals has received final approval from the USFDA for its generic Diltiazem Hydrochloride extended-release capsules, used to treat hypertension. The approval covers multiple strengths and is therapeutically equivalent to Allergan's Dilacor XR.
Alembic Pharma Secures USFDA Approval for Diltiazem - 21 Oct, 2024
Alembic Pharmaceuticals has received final USFDA approval for its Diltiazem Hydrochloride extended-release capsules, available in 120 mg, 180 mg, and 240 mg strengths, used for hypertension treatment. This approval enhances Alembic's market presence, with an estimated market size of $28.2 million for the product.
Alembic Pharma Secures USFDA Approval for Capsules - 20 Oct, 2024
Alembic Pharmaceuticals has received final USFDA approval for Diltiazem Hydrochloride Extended-Release Capsules, strengthening its portfolio with a total of 217 ANDA approvals.
Insights on Alembic Pharmaceuticals Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTProfit Spike
Netprofit is up for the last 2 quarters, 134.71 Cr → 153.41 Cr (in ₹), with an average increase of 12.2% per quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 3 quarters, 1.52K Cr → 1.67K Cr (in ₹), with an average increase of 4.8% per quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 8.05% to 8.90% in Sep 2024 quarter
NO EFFECTAgainst Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 130.6% return, outperforming this stock by 89.2%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 69.61% of holdings in Sep 2024 quarter
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 58.6% return, outperforming this stock by 18.6%
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 4.32% to 3.94% in Sep 2024 quarter
- NEGATIVE IMPACT
Price Dip
In the last 1 month, APLLTD stock has moved down by -8.8%
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 10.60% to 10.39% in Sep 2024 quarter
Alembic Pharmaceuticals Ltd Financials
Index Inclusions
Alembic Pharmaceuticals Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 69.61% | 0.00 | |
| Foreign Institutions | 3.94% | ||
| Mutual Funds | 8.9% | 10.53 | |
| Retail Investors | 10.39% | ||
| Others | 7.16% |
Alembic Pharmaceuticals Ltd Key Indicators
Alembic Pharmaceuticals Ltd Valuation
Alembic Pharmaceuticals Ltd in the last 5 years
Lowest (11.53x)
March 23, 2020
Today (32.17x)
November 19, 2024
Industry (54.42x)
November 19, 2024
Highest (53.41x)
January 3, 2023
Alembic Pharmaceuticals Ltd Earnings and Dividends
Alembic Pharmaceuticals Ltd Earnings Results
Alembic Pharmaceuticals Ltd’s net profit jumped 12.34% since last year same period to ₹153.41Cr in the Q2 2024-2025. On a quarterly growth basis, Alembic Pharmaceuticals Ltd has generated 13.88% jump in its net profits since last 3-months.
Read More about Earnings ResultsAlembic Pharmaceuticals Ltd Dividends May,2024
In the quarter ending March 2024, Alembic Pharmaceuticals Ltd has declared dividend of ₹11 - translating a dividend yield of 1.06%.
Read More about Dividends
Alembic Pharmaceuticals Ltd Technicals Summary
Bearish
Neutral
Bullish
Alembic Pharmaceuticals Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Alembic Pharmaceuticals Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Alembic Pharmaceuticals Ltd shares.
Alembic Pharmaceuticals Ltd (APLLTD) share price today is ₹1037.85
Alembic Pharmaceuticals Ltd is listed on NSE
Alembic Pharmaceuticals Ltd is listed on BSE
- Today’s highest price of Alembic Pharmaceuticals Ltd is ₹1043.4.
- Today’s lowest price of Alembic Pharmaceuticals Ltd is ₹1020.65.
PE Ratio of Alembic Pharmaceuticals Ltd is 32.17
PE ratio = Alembic Pharmaceuticals Ltd Market price per share / Alembic Pharmaceuticals Ltd Earnings per share
Today’s traded volume of Alembic Pharmaceuticals Ltd(APLLTD) is 54.80K.
Today’s market capitalisation of Alembic Pharmaceuticals Ltd(APLLTD) is ₹20449.44Cr.
| Alembic Pharmaceuticals Ltd(APLLTD | Price |
|---|---|
52 Week High | ₹1303.9 |
52 Week Low | ₹710.25 |
Alembic Pharmaceuticals Ltd(APLLTD) share price is ₹1037.85. It is down -20.40% from its 52 Week High price of ₹1303.9
Alembic Pharmaceuticals Ltd(APLLTD) share price is ₹1037.85. It is up 46.12% from its 52 Week Low price of ₹710.25
| Alembic Pharmaceuticals Ltd(APLLTD | Returns |
|---|---|
1 Day Returns | -2.5% |
1 Month Returns | -8.8% |
3 Month Returns | -6.04% |
1 Year Returns | 39.97% |